← Back to all trials
Not Yet Recruiting
NCT05701384
Lazertinib 160mg in EGFR T790M NSCLC
Conditions: Lung Cancer Stage IV, EGFR T790M
Sex: All
Ages: 19 Years – N/A
Phase: PHASE2
Enrollment: 117
Sponsor: Samsung Medical Center
Location: Korea, Republic of
Summary
The lazertinib is currently approved as 2nd line T790M mutation-positive NSCLC that failed from either 1st or 2nd generation EGFR TKI.
The current recommended dosage is 240mg.
Based on the promising clinical efficacy of the dose escalation study, this study is designed to evaluatee the clinical efficacy and safety of 160mg lazertinib.
Eligibility Criteria
Inclusion Criteria:Pathologically confirmed non-small cell lung cancerPatients in a palliative setting who is not applicable for the curative treatmentEGFR mutation positive patients who received previous 1st or 2nd generation EGFR TKIConfirmed EGFR T790M mutation after the previous EGFR TKIAvailable to receive lazertinib either as po or vis levine tubeWilling to participate clinical trialAge over or equal to 19ECOG PS 0 to 2Exclusion Criteria:Previously received 3rd generation EGFR TKINo clinical benefit is expected based on the investigator's decisionUncontrolled symptomatic CNS metastasesUncontrolled systemic disease
Source: ClinicalTrials.gov (NCT05701384). StuddyBuddy aggregates publicly available trial information.
